Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

320
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

464
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
464
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Pneumothorax-II01:27

Pneumothorax-II

852
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
852
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.1K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

MRE11 Deficiency Occurs in a Small Group of Cancers from Various Different Tumor Entities.

Diagnostics (Basel, Switzerland)·2026
Same author

A case of Schöpf-Schulz-Passarge syndrome presented with widespread apocrine hidrocystomas showing variable clinical features.

Acta dermatovenerologica Croatica : ADC·2026
Same author

Prevalence of heterozygous and homozygous 9p21 deletions in human cancer: a tissue microarray study on 4,999 tumors from 125 different tumor types.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Neuromuscular Electrical Stimulation in Brachial Plexus Birth Injury Rehabilitation: A Systematic Review.

Medicina (Kaunas, Lithuania)·2026
Same author

Klinische Padiatrie·2026
Same author

Down Syndrome: From Pregnancy through Childhood in Türkiye.

Molecular syndromology·2026

関連する実験動画

Updated: Jan 8, 2026

Pulmonary Embolism III: Nursing Management
01:27

Pulmonary Embolism III: Nursing Management

Published on: June 19, 2025

320

人間のCLP1変異はtRNAの生体生成を変化させ,外周神経系と中枢神経系の両方の機能に影響を与えます.

Ender Karaca1, Stefan Weitzer2, Davut Pehlivan1

  • 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.

Cell
|April 29, 2014
PubMed
まとめ

RNA処理に不可欠なCLP1遺伝子の変異は,運動機能と脳の発達に影響を与える重度の神経疾患を引き起こす. これは,ヒトの病気における希少な遺伝子変異の役割を強調しています.

さらに関連する動画

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Published on: June 19, 2025

277
Pulmonary Embolism I: Introduction
01:29

Pulmonary Embolism I: Introduction

Published on: June 19, 2025

464

関連する実験動画

Last Updated: Jan 8, 2026

Pulmonary Embolism III: Nursing Management
01:27

Pulmonary Embolism III: Nursing Management

Published on: June 19, 2025

320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Published on: June 19, 2025

277
Pulmonary Embolism I: Introduction
01:29

Pulmonary Embolism I: Introduction

Published on: June 19, 2025

464

科学分野:

  • 神経科学は神経科学である.
  • 遺伝学 遺伝学とは
  • 分子生物学は分子生物学である.

背景:

  • CLP1 (CASEIN LYSINE RICH PROTEIN 1) は,tRNAのスプライシングに不可欠なRNAキナーゼである.
  • ネズミのキナーゼデッドCLP1は,モーターニューロンの喪失と麻痺を含む神経筋疾患を引き起こす.
  • 神経学的発達におけるCLP1の役割は,ますます認識されています.

研究 の 目的:

  • 人間の神経疾患におけるCLP1変異の役割を調査する.
  • CLP1に関連した神経学的現象型の基礎にある分子メカニズムを解明する.
  • 病気の病因学における希少な遺伝的変異の重要性を探求する.

主な方法:

  • ヒトゲノム解析により,罹患家族におけるCLP1変異を特定する.
  • バイオケミカルアッセイは,TSEN複合体とCLP1の相互作用と,tRNA分裂前の活性性を評価するものです.
  • 罹患者のフェノタイプ分析とCLP1キナーゼで死亡したマウスモデル.

主要な成果:

  • 5つのファミリーで同胞性CLP1ミッセンスの変異 (p.R140H) が特定され,TSEN複合体との相互作用の喪失を引き起こしました.
  • 変異は,tRNA前分裂の減少,線形tRNAイントロンの蓄積,および重度の運動感覚の欠陥につながった.
  • 罹患した個人やマウスは,神経原始細胞の死滅が増加したため,小頭症と皮質変性を発症した.

結論:

  • CLP1変異はtRNAのスプライシングを阻害し,独特の神経症候群を引き起こす.
  • この研究は,神経細胞の発達と脳形成におけるCLP1の重要な役割を強調しています.
  • この研究は,希少な遺伝子変異の重要性を強調し,クランゲノミクス仮説を支持しています.